Drug intelligence / Profile preview

THOR-213

Development stage: Unknown
Lead developer: THOR Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

THOR-213 is an antisense oligonucleotide (ASO) therapeutic candidate developed by THOR Biopharma. It is designed to target the Macrophage Migration Inhibitory Factor (MIF) and its cognate receptor CD74, effectively inhibiting the MIF-CD74 signaling axis. This axis is known to play a critical role in promoting pro-inflammatory environments and tumor progression. By reducing the expression of these components through antisense-mediated knockdown, THOR-213 aims to treat diseases where MIF-CD74 signaling is dysregulated, such as autoimmune disorders and various cancers. The program is currently in the preclinical stage of development, specifically undergoing candidate optimization.

Targets

CD74 (Major histocompatibility complex class II invariant chain)Macrophage migration inhibitory factor mRNA

Beyond the preview

Go deeper on THOR-213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THOR-213.

Explore the full profile